March 2026 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.
January 2018 in “Surgical and Cosmetic Dermatology” This review provides an in-depth examination of the efficacy and safety of finasteride and dutasteride, commonly used for treating benign prostatic hyperplasia and male androgenetic alopecia.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
This research review concluded that 5α-reductase inhibitors may be effective in treating androgenetic alopecia, showing general efficacy over placebo, though future clinical trials are needed to determine the best drug, dose, and duration, as well as gender differences in treatment response.
July 2025 in “Saudi Journal of Medicine and Public Health” In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.